Clinical Trial

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Sjögren's syndrome (SS) is a chronic autoimmune disease primarily affecting the salivary and lacrimal glands, leading to symptoms of dryness. Assessing the inflammatory activity is crucial for guiding treatment. Fibroblast activation protein (FAPI) PET is an emerging imaging technique increasingly used for evaluating various inflammations and tumors. Thus this prospective study is going to investigate the uptake characteristics of FAPI PET in Sjögren's syndrome and evaluate its potential in assessing inflammatory activity to guide clinical treatment. A control group of tumor patients undergoing FAPI PET imaging will be included to compare FAPI uptake patterns between autoimmune inflammation and neoplasia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-08.
Trial Details
NCT Number NCT07062523
Lead Sponsor Peking Union Medical College Hospital
Conditions Sjogren's Syndrome
Enrollment 60 participants
Start Date 2024-07-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-01